PDGFRB and Hand-foot syndrome: In our study, we observed a different prevalence of HFS in sorafenib and lenvatinib groups, with more cases and more severe toxicity under sorafenib therapy, which could probably be explained by the different inhibition potency of the two drugs for VEGFR and PDGFR (Supplementary Table 2).